sandoz News
Most Popular sandoz Story
Momenta sees delay in generic Lovenox development
Shares of Momenta took a hit after the company warned that its development of a generic version of Sanofi's blood thinner Lovenox is likely to take longer than expected. Shares slid 15 percent on the news that the regulatory review of its abbreviated new drug application would take longer than the 18 to 24 months originally expected. Momenta is developing M-Enoxaparin with Sandoz, the generic arm of Novartis. Momenta is considered one of the key players in the development of a new …
... Read more...Latest Headlines
- November 7, 2007
- November 6, 2007
- August 31, 2007
- June 28, 2007
- December 20, 2006
- May 30, 2006
- May 3, 2006
- April 17, 2006
- April 16, 2006
- April 16, 2006
- January 26, 2006
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


